June 15, 2026
|
The Honorable Mehmet Oz, M.D.
|
|
Re: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children’s Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges [CMS-0062-P]
Dear Administrator Oz,
On behalf of our member medical group practices, the Medical Group Management Association (MGMA) appreciates the opportunity to provide comments to the Centers for Medicare & Medicaid Services (CMS) on the Notice of Proposed Rulemaking (proposed rule) for the 2026 Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P). The proposed rule was published on the Federal Register on April 14, 2026, and builds on the 2024 CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) and CMS Interoperability and Patient Access Final Rule (CMS-9115-F).
MGMA strongly supports CMS’s outlined proposals to advance interoperability and improve prior authorization for prescription drugs, which, if implemented correctly, would help support patient care and improve medical group operations. Our comments provide further recommendations and clarifications to help CMS successfully achieve key objectives.
